JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

MacroGenics Inc

Затворен

СекторЗдравеопазване

1.68 -9.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.6600000000000001

Максимум

1.85

Ключови измерители

By Trading Economics

Приходи

4.8M

-36M

Продажби

9M

22M

Марж на печалбата

-162.992

Служители

341

EBITDA

5.7M

-33M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+102.7% upside

Дивиденти

By Dow Jones

Следващи печалби

4.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

28M

121M

Предишно отваряне

10.87

Предишно затваряне

1.68

Настроения в новините

By Acuity

67%

33%

154 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.10.2025 г., 23:28 ч. UTC

Горещи акции

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29.10.2025 г., 23:07 ч. UTC

Печалби

Prudential PLC 3Q New Business Profit Up 13%

30.10.2025 г., 00:00 ч. UTC

Печалби

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30.10.2025 г., 00:00 ч. UTC

Печалби

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30.10.2025 г., 00:00 ч. UTC

Печалби

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29.10.2025 г., 23:40 ч. UTC

Печалби

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29.10.2025 г., 23:25 ч. UTC

Печалби

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29.10.2025 г., 22:51 ч. UTC

Печалби

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29.10.2025 г., 22:45 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29.10.2025 г., 22:41 ч. UTC

Печалби

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29.10.2025 г., 22:41 ч. UTC

Печалби

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29.10.2025 г., 22:09 ч. UTC

Печалби

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29.10.2025 г., 22:08 ч. UTC

Пазарно говорене
Печалби

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29.10.2025 г., 21:58 ч. UTC

Печалби

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29.10.2025 г., 21:58 ч. UTC

Печалби

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29.10.2025 г., 21:57 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29.10.2025 г., 21:54 ч. UTC

Печалби

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29.10.2025 г., 21:46 ч. UTC

Печалби

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29.10.2025 г., 21:43 ч. UTC

Печалби

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29.10.2025 г., 21:43 ч. UTC

Печалби

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29.10.2025 г., 21:42 ч. UTC

Печалби

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29.10.2025 г., 21:42 ч. UTC

Печалби

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29.10.2025 г., 21:41 ч. UTC

Печалби

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29.10.2025 г., 21:41 ч. UTC

Печалби

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29.10.2025 г., 21:41 ч. UTC

Печалби

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29.10.2025 г., 21:41 ч. UTC

Печалби

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29.10.2025 г., 21:40 ч. UTC

Печалби

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29.10.2025 г., 21:39 ч. UTC

Печалби

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

102.7% нагоре

12-месечна прогноза

Среден 3.75 USD  102.7%

Висок 5 USD

Нисък 3 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

6 ratings

3

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

Краткосрочен план

Neutral Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

154 / 373 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat